Drugmakers Increase Prices on Over 250 Medications
Key Points: 1. Over 250 branded drugs saw price increases in the U.S., including Paxlovid and cancer therapies. 2. Median...
Pharma
Novartis and Sanofi Urge EU to Raise Drug Prices
Key Points: 1. European pharma leaders push for higher drug prices to boost global competitiveness. 2. CEOs warn EU may...
Eli Lilly Takes Legal Action Against Telehealth Startups
Key Points: 1. Lilly sues four telehealth firms for unauthorized compounding of Mounjaro and Zepbound. 2. GLP 1 drugs remain...
FDA Approves Dupilumab for Chronic Spontaneous Urticaria
Key Points: 1. FDA approves Dupixent as the first new CSU treatment in over a decade. 2. Phase 3 trial...
![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/ChatGPT-Image-May-12-2025-at-10_22_23-AM-350x250.png)
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Drugmakers Increase Prices on Over 250 Medications Pharmaceutical companies have raised prices on over 250 branded medications in the U.S.,...
Safety of investigational vaccines against human immunodeficiency virus
1. In this phase 1 randomized controlled trial, urticaria was reported in several participants who received a messenger RNA vaccine...
Sotorasib plus panitumumab may be a promising treatment option for colorectal cancer
1. While not statistically significant, the use of sotorasib plus panitumumab may have a 30% relative risk reduction in the...
Mirum: Ctexli reduces cholesterol metabolite build-up in patients with cerebrotendinous xanthomatosis
Ctexli significantly reduced levels of two atypical cholesterol metabolites usually elevated in patients with cerebrotendinous xanthomatosis (CTX) compared to the...
Increased tirzepatide use for glycemic and weight control since United States market entry
1. In this retrospective cohort study, tirzepatide dispensations were found to have increased significantly following approval in the United States...
Imlunestrant extends progression-free survival in ER-positive, HER2-negative breast cancer
1. In this randomized controlled trial, in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced...